title: Recent advances in the treatment of ARDS.
abstract: Despite more than 25 years of extensive research the mortality of ARDS patients remains high. Besides the often deleterious course of the underlying disease, another reason for this high mortality lies in the aggressive ventilatory regimen which is required to maintain arterial blood gases in a more or less normal range. Therapeutic methods which are used to reduce iatrogenic damage to the lungs are pressure controlled ventilation with permissive hypercapnia, differential lung ventilation, positioning therapy, dehydration, and extracorporeal gas exchange with membrane lungs. Nevertheless, many of these patients still die following hypoxaemia or multiple organ failure. Therefore, the need remains to develop new therapeutic strategies and to investigate their influence on the morbidity and mortality of this life-threatening disease. First experiences with nitric oxide (NO) inhalation, intravenous application of antioxidants, intratracheal instillation of surfactant, tracheal gas insufflation and combined fluid/gas ventilation with perfluorocarbon are presented. All these new methods have proved their efficacy, at least in animal studies, however, they should still be regarded as experimental.
authors.affiliation: Klinik für Anaesthesiologie und operative Intensivmedizin, Virchow Klinikum, Medizinische Fakultät, Humboldt-Universität, Berlin, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Rossaint
authors.forename: D
authors.initials: D
authors.lastname: Pappert
authors.forename: G
authors.initials: G
authors.lastname: Fritz
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D002245:Carbon Dioxide / Q000097:blood; D003131:Combined Modality Therapy; D011464:Epoprostenol / Q000008:administration & dosage; D005466:Fluorocarbons / Q000008:administration & dosage; D006801:Humans; D006861:Hydrogen Peroxide / Q000627:therapeutic use; D009569:Nitric Oxide / Q000008:administration & dosage; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D012121:Respiration, Artificial / Q000379:methods; D012128:Respiratory Distress Syndrome / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D012138:Respiratory Therapy; D012756:Sheep; D013482:Superoxide Dismutase / Q000627:therapeutic use